LIGAND PHARMACEUTICALS INCORPORATED
Cash Flow Statement
| Line Item | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $12.6M | $-1.6M | $229.8M | $12.0M | $11.4M | $-527.0K | $9.7M | $-10.4M |
| Depreciation & Amortization | $11.0M | $11.3M | $2.6M | $2.7M | $2.7M | $2.7M | $2.8M | $2.2M |
| Depreciation | $400.0K | $200.0K | $200.0K | $300.0K | $300.0K | $300.0K | $500.0K | $2.1M |
| Amortization | $12.1M | $10.6M | $2.4M | $2.4M | $2.4M | $2.4M | $2.3M | $100.0K |
| Stock-Based Compensation | $24.9M | $18.9M | $12.5M | $11.3M | $5.7M | $4.1M | $3.4M | $2.3M |
| Net Cash from Operating Activities | $88.6M | $60.7M | $41.7M | $20.6M | $20.7M | $161.0K | $-1.2M | $-27.1M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.2M | $1.9M | $93.0K | $6.0K | $377.0K | $595.0K | $78.0K | $70.0K |
| Business Acquisitions | $26.7M | $92.5M | $0 | $0 | $3.6M | $0 | $0 | $2.8M |
| Net Cash from Investing Activities | $-79.2M | $-134.4M | $-112.9M | $-2.0M | $-5.0M | $1.3M | $-25.1M | $14.5M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | $2.0M | $3.9M | $489.0K | $68.0M | $0 | $0 | $55.0K | $91.0K |
| Net Cash from Financing Activities | $-7.5M | $-5.0M | $8.4M | $130.0M | $-16.5M | $3.9M | $30.0M | $-159.0K |
| Net Change in Cash | $1.9M | $-78.7M | $-62.8M | $148.6M | $-742.0K | $5.3M | $3.7M | $-12.7M |
| Free Cash Flow | $86.4M | $58.9M | $41.6M | $20.6M | $20.3M | $-434.0K | $-1.3M | $-27.1M |